SmiLe Inject Capital, based in Lund, Sweden, has announced an investment of SEK 9 million (€800K) in three life science startups: Uman Sense, Nygen Analytics, and Aligned Bio. These companies are members of the SmiLe Venture Hub and aim to commercialize innovations that could significantly impact global health. The investment aims to support these startups’ growth and enhance their market presence.
Compared to previous announcements, SmiLe Inject Capital continues its trend of investing in promising life science companies. Past investments have focused on early-stage startups with innovative technologies. The emphasis on supporting companies close to market launch remains consistent, highlighting the firm’s strategic approach. The addition of experienced business angels and venture capital from Saminvest reaffirms their commitment to fostering innovation.
With prior investments, SmiLe Inject Capital has successfully nurtured startups, some of which have achieved significant milestones, such as securing further funding and partnerships with key industry players. This investment round aligns with their ongoing mission to drive growth and commercial success for life science innovations.
Focus on Uman Sense, Nygen Analytics, and Aligned Bio
Uman Sense, a medical technology startup from Lund University, has developed the Stroke Alarm, a wristband for stroke risk patients. The device offers continuous monitoring and immediate alerts for rapid intervention. Supported by SmiLe Inject Capital’s SEK 3 million (€265K) investment, Uman Sense plans to conduct efficiency studies and launch its product in the EU market.
Nygen Analytics, founded in 2022, specializes in genomics data analytics. Their cloud-based platform simplifies gene mapping data analysis from individual cells. The technology aims to make drug development data more accessible and accurate. With a SEK 2 million (€176K) investment from SmiLe Inject Capital, Nygen Analytics will enhance its technical development and market positioning.
Aligned Bio’s Innovative Approach
Aligned Bio, established in 2019, focuses on nanowire-based biosensor technology for disease diagnostics and genome sequencing. The company’s platform offers higher sensitivity and the ability to analyze longer DNA fragments. SmiLe Inject Capital’s SEK 4 million (€353K) investment will support Aligned Bio’s technical development and production scaling.
Thomas Unt, CEO of SmiLe Inject Capital, stated, “SmiLe Inject has seen great potential for rapid commercial success in all these investments. All companies are close to market launch and have been working for a long time with strategic partners.”
“Our hope is that their respective innovative technologies and strong teams have the potential to reach critical milestones to ensure commercial impact,” Unt added.
SmiLe Venture Hub in Lund, Sweden, offers comprehensive support for life science startups from concept to commercialization. It provides incubation, acceleration programs, educational courses, and access to top-tier lab facilities. SmiLe has assisted over 100 startups in securing more than €841 million in venture capital and achieving 21 IPOs. The hub is supported by various regional and academic entities, ensuring a robust ecosystem for innovation.
The recent investments by SmiLe Inject Capital underscore their strategic focus on accelerating life science startups with strong potential for market success. Supporting these companies with significant funding and resources is expected to drive innovation and commercialization in the health sector. This approach is crucial as the demand for advanced medical technologies continues to grow, highlighting the importance of fostering early-stage innovations to address global health challenges.
